Brookdale Senior Living Inc. BKD

NYSE; healthcare; SIC 8050, Services-Nursing & Personal Care Facilities; CIK 0001332349

E

weakest fifth of 370 graded peers in healthcare

rank 331 of 370; percentile 89.4; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	C/D percentile 62.1
Solvency	D percentile 75.4
Growth and financing	D percentile 67.7
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $6.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	12 of 14
Graded from	filings received through Feb 19, 2026 247 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$10.08 2026-10-23; market equity $2.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Unless otherwise specified, references to "Brookdale," "we," "us," "our," or "the Company" in this Annual Report on Form 10-K mean Brookdale Senior Living Inc. together with its consolidated subsidiaries. We are the nation's premier operator of senior living communities, operating and managing 584 communities in 41 states as of December 31, 2025, with the ability to serve approximately 51,000 residents. We offer our residents access to a broad continuum of services across the most attractive sectors of the senior living industry. We operate and manage independent living, assisted living, memory care, and continuing care retirement communities ("CCRCs").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 62.1						
Gross profitability	14.1%	32.3%		70.8	368	2025-12-31
Return on invested capital	0.3%	9.3%		74.0	74	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(7.8%)	(6.6%)	50.1	809	2025-12-31
Gross margin stability, five years	3.1 pts	2.8 pts	53.5	242	2025-12-31
Solvency, sleeve percentile 75.4					
Twelve-month failure probability	0.20%	0.07%	69.5	247	2026-06-30
Altman Z double-prime	(2.36)	(0.33)	47.1	754	2025-12-31
Net debt to EBITDA	10.46x	1.82x	94.6	75	2025-12-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	0.98x	2.94x	90.2	836	2025-12-31
Growth and financing, sleeve percentile 67.7					
Revenue growth, three-year compound	4.2%	10.1%	61.9	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	(865.3%)	37.1%	98.1	104	2025-12-31
Asset growth, three years	0.09%	2.1%	51.5	702	2025-12-31
Net share issuance, one year	18.8%	2.5%	59.4	634	2026-02-17

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
326	Intelligent BIO Solutions Inc. (INBS)	88.1	E	dilution, short runway
327	Maravai Lifesciences Holdings, Inc. (MRVI)	88.3	E	late filer
328	Insight Molecular Diagnostics Inc. (IMDX)	88.6	E	fortress balance sheet
329	Nuwellis, Inc. (NUWE)	88.9	E	dilution, short runway, fortress balance sheet
330	Aclaris Therapeutics, Inc. (ACRS)	89.2	E	short runway, fortress balance sheet
331	Brookdale Senior Living Inc. (BKD)	89.4	E	
332	Lifeward Ltd. (LFWD)	89.7	E	dilution, late filer
333	Canopy Growth Corp. (CGC)	90.0	E	dilution, fortress balance sheet
334	Aytu Biopharma, Inc. (AYTU)	90.2	E	fortress balance sheet
335	Q32 Bio Inc. (QTTB)	90.5	E	
336	Editas Medicine, Inc. (EDIT)	90.8	E	fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	39.2%	7.7%	71
Distance from 52-week high	(39.9%)	(31.4%)	37
EBIT to enterprise value	0.2%	(1.5%)	55
Free cash flow yield	0.7%	(1.0%)	58
Book value to price	(0.01)	0.28	10
Sales to price	1.33	0.30	86

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	26.4%	20.5%	54
Relative strength against the sector, log excess return	0.12	(0.14)	71

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$370.4M
Operating cash flow, four quarters	$223.9M
Months of runway	not finite
Days since last periodic filing	75 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$51.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$837.5M	2025-12-31	2026-02-19	10-K	26-000032
2	assets	us-gaap:Assets	$6.0B	2025-12-31	2026-02-19	10-K	26-000032
3	operating income	us-gaap:OperatingIncomeLoss	$13.5M	2025-12-31	2026-02-19	10-K	26-000032
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$264.7M	2025-12-31	2026-02-19	10-K	26-000032
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$2.0M	2025-12-31	2026-02-19	10-K	26-000032
6	total debt	us-gaap:LongTermDebt	$4.3B	2025-12-31	2026-02-19	10-K	26-000032
7	book equity	us-gaap:StockholdersEquity	-$44.8M	2025-12-31	2026-02-19	10-K	26-000032
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$279.1M	2025-12-31	2026-02-19	10-K	26-000032
9	total debt	us-gaap:LongTermDebt	$4.1B	2024-12-31	2026-02-19	10-K	26-000032
10	book equity	us-gaap:StockholdersEquity	$212.5M	2024-12-31	2026-02-19	10-K	26-000032
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$308.9M	2024-12-31	2026-02-19	10-K	26-000032
12	net income	us-gaap:NetIncomeLoss	-$262.7M	2025-12-31	2026-02-19	10-K	26-000032
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$218.0M	2025-12-31	2026-02-19	10-K	26-000032
14	assets	us-gaap:Assets	$6.3B	2024-12-31	2026-02-19	10-K	26-000032
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.2B	2025-12-31	2026-02-19	10-K	26-000032
16	gross profit	us-gaap:GrossProfit	$799.3M	2024-12-31	2026-02-19	10-K	26-000032
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.1B	2024-12-31	2026-02-19	10-K	26-000032
18	gross profit	us-gaap:GrossProfit	$746.7M	2023-12-31	2026-02-19	10-K	26-000032
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.0B	2023-12-31	2026-02-19	10-K	26-000032
20	gross profit	us-gaap:GrossProfit	$594.4M	2022-12-31	2025-02-19	10-K	25-000037
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2022-12-31	2025-02-19	10-K	25-000037
22	gross profit	us-gaap:GrossProfit	$501.0M	2021-12-31	2024-02-21	10-K	24-000041
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2021-12-31	2024-02-21	10-K	24-000041
24	current assets	us-gaap:AssetsCurrent	$553.9M	2025-12-31	2026-02-19	10-K	26-000032
25	current liabilities	us-gaap:LiabilitiesCurrent	$567.9M	2025-12-31	2026-02-19	10-K	26-000032
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$4.3B	2025-12-31	2026-02-19	10-K	26-000032
27	liabilities	us-gaap:Liabilities	$6.0B	2025-12-31	2026-02-19	10-K	26-000032
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$370.3M	2025-12-31	2026-02-19	10-K	26-000032
29	operating income	us-gaap:OperatingIncomeLoss	$18.4M	2023-12-31	2026-02-19	10-K	26-000032

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$238.3M	2023-12-31	2024-02-21	10-K	24-000041
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$201.5M	2025-12-31	2026-02-19	10-K	26-000032
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$166.2M	2024-12-31	2026-02-19	10-K	26-000032
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$201.2M	2024-12-31	2026-02-19	10-K	26-000032
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$162.9M	2023-12-31	2026-02-19	10-K	26-000032
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$233.2M	2023-12-31	2026-02-19	10-K	26-000032
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.3M	2022-12-31	2025-02-19	10-K	25-000037
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$196.9M	2022-12-31	2025-02-19	10-K	25-000037
38	current assets	us-gaap:AssetsCurrent	$512.9M	2024-12-31	2026-02-19	10-K	26-000032
39	current liabilities	us-gaap:LiabilitiesCurrent	$579.8M	2024-12-31	2026-02-19	10-K	26-000032
40	assets	us-gaap:Assets	$5.6B	2023-12-31	2025-02-19	10-K	25-000037
41	assets	us-gaap:Assets	$5.9B	2022-12-31	2024-02-21	10-K	24-000041
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	237,792,413	2026-02-17	2026-02-19	10-K	26-000032
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	200,189,063	2025-02-17	2025-04-29	10-K/A	25-103994

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.